Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

ALS researcher Merit Cudkowicz to receive MDA legacy award

Renowned neurologist and amyotrophic lateral sclerosis (ALS) investigator Merit Cudkowicz, MD, of Massachusetts General Hospital has been named this year’s recipient of the Muscular Dystrophy Association (MDA) Legacy Award for Achievement in Clinical Research. The award, which recognizes outstanding accomplishments in neuromuscular research, will be presented March 20…

Georgia Southern adding to voice bank for ALS patients, others

To help those who have lost their ability to speak easily, Georgia Southern University’s RiteCare Center for Communications Disorders again is recruiting students, faculty, and staff members to make recordings for submission to a voice bank. The center’s third annual Voice Drive, which runs through May 2, is…

Cytokinetics’ Communications Grants Awarded to 2 ALS Groups

Cytokinetics has awarded $20,000 grants to five patient advocacy organizations, including two serving the amyotrophic lateral sclerosis (ALS) community, under its fifth annual Communications Grant Program. Each grant is intended to support the nonprofit’s outreach, engagement, and awareness efforts, allowing the organizations to broaden their work in underserved…

MDA Awards $600K to Support Neuromodulator in Slowing ALS

The Muscular Dystrophy Association (MDA) has invested $600,000 in PathMaker Neurosystems to help bring a potential noninvasive neuromodulator for amyotrophic lateral sclerosis (ALS) into an initial clinical trial. Funding through the MDA Venture Philanthropy (MVP) program will support an early feasibility study in a small…

Inflamed Pharma, University Collaborate on ProcCluster

Inflamed Pharma, part of the incubator and accelerator company Xlife Sciences, is partnering with researchers at the University Medical Center Gottingen in Germany to develop its investigational therapy ProcCluster for the treatment of amyotrophic lateral sclerosis (ALS). The collaboration, led by Jan C. Koch, MD, a principal investigator…

Northeast Community PTA Students Raise $1,200+ for ALS Research

For the last 15 years, students in the physical therapy assistant (PTA) program at Northeast Community College in Norfolk, Nebraska have participated in a local amyotrophic lateral sclerosis (ALS) event that seeks to raise awareness about the progressive neurodegenerative disorder — and raise the funds to fight it. This…

ALS Success Story Delivers Man’s ‘Most Special Day’

The Lifestyle Healing Institute (LHI), which uses a complementary and alternative medicine approach to care, is touting the success of an amyotrophic lateral sclerosis (ALS) patient whose mobility and quality of life are said to have improved following treatment. The case of Tod, a 60-year-old patient, demonstrates that…

Nearly 2,000 ALS Patients in US Being Treated With Radicava ORS

Nearly 2,000 amyotrophic lateral sclerosis (ALS) patients in the United States have been treated with Radicava ORS (edaravone) since the oral suspension formulation became available there in May, the therapy’s U.S. marketer, Mitsubishi Tanabe Pharma America (MTPA), announced. This formulation is seen to be as equally effective as Radicava, an…